New Research Report on Ophthalmology Therapeutics Market to 2018 by MarketResearchReports
MarketResearchReports.biz Publishes Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eyleas Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)
Albany, NY, February 27, 2013 --(PR.com)-- Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eyleas Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)
GBI Research, the leading business intelligence provider, has released its latest research, "Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eyleas Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)", which provides insights into the global ophthalmology therapeutics market, with forecasts until 2018. The report provides an in-depth analysis of the key therapeutic indications of ophthalmology, namely glaucoma, allergic conjunctivitis, Dry Eye Syndrome (DES), Diabetic Macular Edema (DME), and Wet Age Macular Degeneration (Wet-AMD). The report also examines the ophthalmology therapeutics treatment usage patterns for the covered indications. In addition, the report includes insights into the ophthalmology R&D pipeline.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.
To Buy The Copy Of This Report Visit: http://www.marketresearchreports.biz/analysis-details/ophthalmology-therapeutics-market-to-2018-dosing-convenience-and-cost-effectiveness-continue-to-drive-eyleas-prescription-share-in-wet-age-related-macular-degeneration-wet-amd
In 2011, the global ophthalmology therapeutics market was estimated to be around $10 billion, growing at a Compound Annual Growth Rate (CAGR) of 7.2% between 2004 and 2011. The glaucoma market was the largest segment followed by Wet-AMD. These segments accounted for 36% and 32% of the global ophthalmology therapeutics market in 2011, respectively. The decline in glaucoma revenue due to significant generic erosion will change the therapeutic landscape until 2018, when glaucoma is expected to account for 23%, a decline of 13% relative to 2011, and the wet-AMD market is expected to account for 37% of the global ophthalmology market, an increase of 5% relative to 2011. The decline in the glaucoma market is expected to be offset by a healthy growth in the wet-AMD, DME, and DES markets. These markets are expected to grow due to the presence of considerable unmet need and increasing treatment-seeking and diagnosis rates.
The top pharmaceutical companies in the ophthalmology market are Pfizer Inc., Allergan Inc., Alcon Inc, Novartis AG., Merck & co. Inc and Roche. Approximately 70% of the market is covered by these six companies.
Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the glaucoma, allergic conjunctivitis, DES, DME, and wet-AMD therapeutics market.
Data and analysis for the global ophthalmology therapeutics market
Annualized market data for the ophthalmology therapeutics market from 2004 to 2011, with forecasts to 2018
Key drivers and restraints that have had a significant impact on the market
The competitive landscape of the global ophthalmology therapeutics market
Key M&A activities and licensing agreements that took place in the ophthalmology therapeutics market
To Read The Complete Report with TOC Kindly Visit: http://www.marketresearchreports.biz/analysis/143281
Reasons to buy
Align your product portfolio to the markets with high growth potential
Develop market entry and market expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the ophthalmology market
Develop key strategic initiatives by understanding the key focus areas and leading companies
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
For More Information Contact:
Hemendra Parmar
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
sales@marketResearchReports.biz
website: http://www.marketresearchreports.biz/
Blog: http://mrrbiz.blogspot.ch/
GBI Research, the leading business intelligence provider, has released its latest research, "Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eyleas Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)", which provides insights into the global ophthalmology therapeutics market, with forecasts until 2018. The report provides an in-depth analysis of the key therapeutic indications of ophthalmology, namely glaucoma, allergic conjunctivitis, Dry Eye Syndrome (DES), Diabetic Macular Edema (DME), and Wet Age Macular Degeneration (Wet-AMD). The report also examines the ophthalmology therapeutics treatment usage patterns for the covered indications. In addition, the report includes insights into the ophthalmology R&D pipeline.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.
To Buy The Copy Of This Report Visit: http://www.marketresearchreports.biz/analysis-details/ophthalmology-therapeutics-market-to-2018-dosing-convenience-and-cost-effectiveness-continue-to-drive-eyleas-prescription-share-in-wet-age-related-macular-degeneration-wet-amd
In 2011, the global ophthalmology therapeutics market was estimated to be around $10 billion, growing at a Compound Annual Growth Rate (CAGR) of 7.2% between 2004 and 2011. The glaucoma market was the largest segment followed by Wet-AMD. These segments accounted for 36% and 32% of the global ophthalmology therapeutics market in 2011, respectively. The decline in glaucoma revenue due to significant generic erosion will change the therapeutic landscape until 2018, when glaucoma is expected to account for 23%, a decline of 13% relative to 2011, and the wet-AMD market is expected to account for 37% of the global ophthalmology market, an increase of 5% relative to 2011. The decline in the glaucoma market is expected to be offset by a healthy growth in the wet-AMD, DME, and DES markets. These markets are expected to grow due to the presence of considerable unmet need and increasing treatment-seeking and diagnosis rates.
The top pharmaceutical companies in the ophthalmology market are Pfizer Inc., Allergan Inc., Alcon Inc, Novartis AG., Merck & co. Inc and Roche. Approximately 70% of the market is covered by these six companies.
Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the glaucoma, allergic conjunctivitis, DES, DME, and wet-AMD therapeutics market.
Data and analysis for the global ophthalmology therapeutics market
Annualized market data for the ophthalmology therapeutics market from 2004 to 2011, with forecasts to 2018
Key drivers and restraints that have had a significant impact on the market
The competitive landscape of the global ophthalmology therapeutics market
Key M&A activities and licensing agreements that took place in the ophthalmology therapeutics market
To Read The Complete Report with TOC Kindly Visit: http://www.marketresearchreports.biz/analysis/143281
Reasons to buy
Align your product portfolio to the markets with high growth potential
Develop market entry and market expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the ophthalmology market
Develop key strategic initiatives by understanding the key focus areas and leading companies
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
For More Information Contact:
Hemendra Parmar
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
sales@marketResearchReports.biz
website: http://www.marketresearchreports.biz/
Blog: http://mrrbiz.blogspot.ch/
Contact
Market Research Reports.biz
Hemendra Parmar
+1-518-618-1030
www.marketresearchreports.biz
Hemendra Parmar
+1-518-618-1030
www.marketresearchreports.biz
Contact
Categories